| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Shannon John Patrick Jr | Chief Executive Officer and Director, Director | C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO | /s/ Beth Hecht, Attorney-in-Fact | 06 Jan 2026 | 0001553595 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XERS | Common Stock | Sale | $176,257 | -24,907 | -0.91% | $7.08 | 2,705,346 | 05 Jan 2026 | Direct | F1, F2 |
| transaction | XERS | Common Stock | Options Exercise | $99,611 | +64,265 | +2.4% | $1.55 | 2,769,611 | 05 Jan 2026 | Direct | |
| transaction | XERS | Common Stock | Options Exercise | $38,961 | +25,136 | +0.91% | $1.55 | 2,794,747 | 05 Jan 2026 | Direct | |
| transaction | XERS | Common Stock | Options Exercise | $11,426 | +2,900 | +0.1% | $3.94 | 2,797,647 | 05 Jan 2026 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XERS | Stock Option (Right to Buy) | Options Exercise | $0 | -64,265 | -100% | $0.000000 | 0 | 05 Jan 2026 | Common Stock | 64,265 | $1.55 | Direct | F3 |
| transaction | XERS | Stock Option (Right to Buy) | Options Exercise | $0 | -25,136 | -100% | $0.000000 | 0 | 05 Jan 2026 | Common Stock | 25,136 | $1.55 | Direct | F4 |
| transaction | XERS | Stock Option (Right to Buy) | Options Exercise | $0 | -2,900 | -2.9% | $0.000000 | 97,100 | 05 Jan 2026 | Common Stock | 2,900 | $3.94 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.040 to $7.350, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | The reporting person received the stock options on February 4, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| F4 | The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| F5 | The reporting person received the stock options on August 26, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
Chief Executive Officer and Director